SI-BONE, Inc. (NASDAQ:SIBN) Director Gregory K. Hinckley Sells 1,179 Shares

Last updated on Wednesday, June 16, 2021 | 2021 MarketBeat

SI-BONE, Inc. (NASDAQ:SIBN) Director Gregory K. Hinckley sold 1,179 shares of the firm's stock in a transaction that occurred on Wednesday, June 16th. The shares were sold at an average price of $31.46, for a total transaction of $37,091.34. Following the completion of the sale, the director now directly owns 72,573 shares in the company, valued at approximately $2,283,146.58. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

SIBN stock traded up $0.79 during midday trading on Wednesday, reaching $31.81. 157,892 shares of the company were exchanged, compared to its average volume of 273,770. The company has a current ratio of 15.18, a quick ratio of 14.64 and a debt-to-equity ratio of 0.24. SI-BONE, Inc. has a 1-year low of $14.43 and a 1-year high of $37.21. The company's 50-day moving average price is $32.45. The company has a market capitalization of $1.04 billion, a P/E ratio of -22.40 and a beta of 1.44.

SI-BONE (NASDAQ:SIBN) last announced its earnings results on Sunday, May 2nd. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.40) by $0.03. The business had revenue of $20.44 million for the quarter, compared to analyst estimates of $19.08 million. SI-BONE had a negative net margin of 56.06% and a negative return on equity of 31.92%. As a group, sell-side analysts predict that SI-BONE, Inc. will post -1.58 EPS for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the company. Northern Trust Corp grew its position in shares of SI-BONE by 9.2% during the fourth quarter. Northern Trust Corp now owns 349,792 shares of the company's stock worth $10,458,000 after acquiring an additional 29,464 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of SI-BONE by 15.0% during the fourth quarter. Renaissance Technologies LLC now owns 249,301 shares of the company's stock worth $7,454,000 after acquiring an additional 32,501 shares during the last quarter. HighTower Advisors LLC purchased a new position in shares of SI-BONE during the first quarter worth approximately $570,000. Lazard Asset Management LLC purchased a new position in shares of SI-BONE during the fourth quarter worth approximately $41,000. Finally, Pura Vida Investments LLC grew its position in SI-BONE by 27.3% in the 4th quarter. Pura Vida Investments LLC now owns 583,559 shares of the company's stock valued at $17,448,000 after buying an additional 125,050 shares during the last quarter. Institutional investors and hedge funds own 89.93% of the company's stock.

Several analysts recently weighed in on the stock. Needham & Company LLC raised their target price on shares of SI-BONE from $34.00 to $42.00 and gave the company a "buy" rating in a report on Tuesday, May 4th. Canaccord Genuity raised their target price on shares of SI-BONE from $39.00 to $40.00 and gave the company a "buy" rating in a report on Tuesday, May 4th. Citigroup assumed coverage on shares of SI-BONE in a report on Tuesday, June 8th. They set a "buy" rating on the stock. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell assumed coverage on shares of SI-BONE in a report on Tuesday, June 8th. They set a "buy" rating and a $40.00 price objective on the stock. Finally, Truist raised their price objective on shares of SI-BONE from $35.00 to $43.00 in a report on Tuesday, May 4th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The company currently has an average rating of "Buy" and an average price target of $38.50.

About SI-BONE

SI-BONE, Inc, a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and Internationally. The company offers iFuse, a minimally invasive surgical implant system, which is intended to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain.

Recommended Story: Hang Seng Index (HSI)

Insider Buying and Selling by Quarter for SI-BONE (NASDAQ:SIBN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Featured Article: What does a market perform rating mean?


7 Stocks That Can Help You Profit From Summer Shortages

One of the lingering impacts of the Covid-19 pandemic is the supply chain disruptions that continue to bedevil many sectors. By now, every investor is aware of the global chip shortage that is disrupting many sectors that were projected to have strong growth in 2021.

But there are many more sectors that are being affected by supply chain disruptions. And this affects everything from big-ticket items like cars to everyday items like pet food and even bacon.

The focus of this special presentation is seven companies that stand to benefit from the current disruption in the supply chain. All of these companies delivered strong gains in 2020. Some of them have weakened in 2021, but that was before the full extent of the supply chain weakness was discovered.

As the economy reopens, the shortage of items is likely to continue and become much more notable. When they do, many of these stocks may get overpriced. That’s why now is the time to get in on these stocks that can help you work the supply chain in your favor.

View the "7 Stocks That Can Help You Profit From Summer Shortages".


MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.